Literature DB >> 21676516

Multicenter analysis of survival and prognostic factors in pathologic stage I non-small-cell lung cancer according to the new 2009 TNM classification.

Pablo León-Atance1, Nicolás Moreno-Mata, Federico González-Aragoneses, Miguel Ángel Cañizares-Carretero, María Dolores García-Jiménez, Marta Genovés-Crespo, Antonio Francisco Honguero-Martínez, Carlos Alberto Rombolá, Carlos María Simón-Adiego, Rafael Peñalver-Pascual.   

Abstract

INTRODUCTION: The new 2009 TNM classification introduced important modifications in lung cancer staging. The aim of this study is to validate our series of patients with pathologic stage I non-small-cell lung cancer according to the 7th edition of the TNM classification of malignant tumors and to the factors related with prognosis. PATIENTS AND METHODS: A multicenter retrospective study was performed. Survival rates were calculated by the Kaplan-Meier method, and for multivariate analyses, Cox proportional hazards regression model was used. The following variables were analyzed: age, sex, pathologic stage, T category, histology, type of resection and tumor size.
RESULTS: A total of 402 patients were included. Mean follow-up was 70.18 months. Overall 5-year survival was 68%. Males and patients over 70 had lower survival. Prognosis worsened with increasing pathologic stage, T category and tumor size. We found no statistically significant differences in prognosis for histology or type of resection. Multivariate analysis showed age, sex and pathologic stage to be independent prognostic factors.
CONCLUSIONS: Survival results and the analysis of prognostic factors in our series are similar to those published in the new 2009 TNM classification. The most important prognostic factor is pathologic stage. Other adverse prognostic factors include male sex and age over 70.
Copyright © 2011 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21676516     DOI: 10.1016/j.arbres.2011.04.004

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  10 in total

Review 1.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

2.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

3.  Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.

Authors:  Helga Sertić Milić; Ana Franjević; Gordana Bubanović; Ante Marušić; Igor Nikolić; Igor Puljić
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

4.  C-reactive protein and serum amyloid a overexpression in lung tissues of chronic obstructive pulmonary disease patients: a case-control study.

Authors:  Jose Luis López-Campos; Carmen Calero; Belén Rojano; Marta López-Porras; Javier Sáenz-Coronilla; Ana I Blanco; Verónica Sánchez-López; Daniela Tobar; Ana Montes-Worboys; Elena Arellano
Journal:  Int J Med Sci       Date:  2013-06-08       Impact factor: 3.738

5.  Factors associated with disease-specific survival of patients with non-small cell lung cancer.

Authors:  Mirian Carvalho de Souza; Oswaldo Gonçalves Cruz; Ana Glória Godoi Vasconcelos
Journal:  J Bras Pneumol       Date:  2016 Sep-Oct       Impact factor: 2.624

6.  NCAPH is negatively associated with Mcl‑1 in non‑small cell lung cancer.

Authors:  Qiuxia Xiong; Songqing Fan; Lincan Duan; Baiyang Liu; Xiulin Jiang; Xiaobo Chen; Chunyan Xiong; Qingyuan Tao; Juan Wang; Hui Zhang; Chuanjiang Chen; Yong Duan
Journal:  Mol Med Rep       Date:  2020-07-28       Impact factor: 2.952

7.  Evaluation of lung parenchyma, blood vessels, and peripheral blood lymphocytes as a potential source of acute phase reactants in patients with COPD.

Authors:  Elena Arellano-Orden; Carmen Calero; Cecilia López-Ramírez; Verónica Sánchez-López; José Luis López-Villalobos; María Abad Arranz; Ana Blanco-Orozco; Remedios Otero-Candelera; José Luis López-Campos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-06-20

8.  Lung Cancer Survival with Current Therapies and New Targeted Treatments: A Comprehensive Update from the Srinagarind Hospital-Based Cancer Registry from (2013 to 2017).

Authors:  Wachiraporn Musika; Supot Kamsa-Ard; Chananya Jirapornkul; Chalongpon Santong; Anakapong Phunmanee
Journal:  Asian Pac J Cancer Prev       Date:  2021-08-01

9.  Cost-Sensitive Uncertainty Hypergraph Learning for Identification of Lymph Node Involvement With CT Imaging.

Authors:  Qianli Ma; Jielong Yan; Jun Zhang; Qiduo Yu; Yue Zhao; Chaoyang Liang; Donglin Di
Journal:  Front Med (Lausanne)       Date:  2022-02-10

10.  Differential expression of C-reactive protein and serum amyloid A in different cell types in the lung tissue of chronic obstructive pulmonary disease patients.

Authors:  Carmen Calero; Elena Arellano; Jose Luis Lopez-Villalobos; Verónica Sánchez-López; Nicolás Moreno-Mata; José Luis López-Campos
Journal:  BMC Pulm Med       Date:  2014-05-30       Impact factor: 3.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.